Full Press Release Details
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher s Disease
CARMIEL, Israel (BUSINESS WIRE) Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX) today announced
the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug
Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase
(GCD) for the potential treatment of Gaucher s disease.
On December 1, 2009, Pfizer and Protalix entered into an agreement to develop and commercialize
taliglucerase alfa for the treatment of Gaucher s disease. The agreement gives Pfizer exclusive
worldwide licensing rights to commercialize taliglucerase alfa while Protalix retains
commercialization rights in Israel.
With this submission, Protalix and Pfizer take a significant step forward in making a
cost-effective treatment alternative available for Gaucher s disease patients, said Dr. David
Aviezer, president and CEO of Protalix. Our global plans include submitting additional regulatory
applications for taliglucerase alfa in the near term.
David Simmons, president and general manager of Pfizer s Established Products Business Unit,
stated, Pfizer has assembled a team of experts with significant orphan and genetic disease
experience dedicated to working with the worldwide Gaucher s disease community. Upon the receipt
of regulatory approvals, we are poised to quickly make taliglucerase alfa available to patients
suffering with Gaucher s disease who are in need of new treatment options.
In addition, Protalix today announced the filing of its proposed pediatric investigation plan to
the pediatric committee of the EMEA for a clinical study in patients between the ages of 2 and 18.
This event triggers a milestone payment of $5 million by Pfizer to Protalix according to the
agreement between the parties. The terms of the agreement calls for $55 million to be paid by
Pfizer to Protalix in connection with certain regulatory milestones.
Taliglucerase alfa has been granted orphan product designation and fast track development status by
FDA. Taliglucerase alfa is currently being provided to Gaucher s patients in the U.S. under an
expanded access protocol, as well as to patients in the European Union under a compassionate use
On December 2, 2009, Protalix held a medical meeting with the principal investigators involved with
the Company s taliglucerase alfa clinical trial program. At the event, the Company shared the full
Phase III trial results that were submitted to FDA in the Company s NDA filing. These data will be
presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February
10-12, in Miami, Florida.
About Gaucher s disease
Gaucher s disease, an inherited condition, is the most prevalent lysosomal storage disorder, with
an incidence of about 1 in 20,000 live births. People with Gaucher s disease do not have enough of
an enzyme, -glucosidase (glucocerebrosidase) that breaks down a certain type of fat
molecule. As a result, lipid engorged cells (called Gaucher cells) amass in different parts of the
body, primarily the spleen, liver and bone marrow. Accumulation of Gaucher cells may cause spleen
and liver enlargement, anemia, excessive bleeding and bruising, bone disease and a number of other
Protalix is a biopharmaceutical company focused on the development and commercialization of
proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based
expression system. Protalix s ProCellEx presents a proprietary method for the expression of
recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale
production of recombinant therapeutic proteins in an environment free of mammalian components and
viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development
programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special
Protocol Assessment with FDA for Gaucher s disease.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ
materially from the statements made. These statements are based on our current beliefs and
expectations as to such future outcomes. Drug discovery and development involve a high degree of
risk. Factors that might cause material differences include, among others, risks relating to: the
successful preclinical development of our product candidates; the completion of clinical trials;
the review process of the FDA, foreign regulatory bodies and other governmental regulatory bodies,
including the FDA s review of any filings we make in connection with the treatment protocol; delays
in the FDA s or other health regulatory authorities approval of any applications we file or
refusals to approve such filings; refusals by such regulatory authorities to approve the marketing
and sale of a drug product even after acceptance of an application we file for any such drug
product; the identification of lead compounds; the risk that we may fail to satisfy certain
conditions relating to grants we have received from the Office of the Chief Scientist of Israel s
Ministry of Industry and Trade which may lead to our being required to refund grants previously
received together with interest and penalties; the risk that the Office of the Chief Scientist may
not deliver to us all of the funds awarded to us; uncertainties related to the ability to attract
and retain partners for our technologies and products under development; and other factors
described in our filings with the Securities and Exchange Commission. Companies in the
pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or
late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary
findings for such clinical trials. Further, even if favorable testing data is generated by
clinical trials of drug products, the FDA may not accept or approve an NDA filed by a
pharmaceutical or biotechnology company for such drug product. Failure to obtain FDA approval of
any of our drug candidates in a timely manner, if at all, will severely undermine our business and
results of operation by reducing our potential marketable products and our ability to generate
corresponding product revenues. Under our approved treatment protocol, UPLYSO might be provided
only to a limited number of patients and only for a limited time. The FDA s
approval of the treatment protocol or the fast track designation will not have any effect on the
FDA s approval of any NDA we file with respect to UPLYSO, if any, and the review by the FDA of any
data from our Phase III clinical development programs in connection with the approval of the
treatment protocol will not have any effect on the FDA s subsequent review of our complete Phase
III clinical trial data in the future. The statements in this release are valid only as of the
date hereof and we disclaim any obligation to update this information.
The Trout Group, LLC
Marcy Nanus, 646-378-2927
BMC Communications Group, LLC
Brad Miles, 212-477-9007 x17